Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune astrocytopathy characterised by attacks of severe optic neuritis and longitudinally extensive transverse myelitis (LETM -- spinal cord lesions extending over three or more vertebral segments). Most cases are associated with antibodies against aquaporin-4 (AQP4-IgG), with a minority being MOG antibody-positive (MOGAD). NMOSD causes more severe attacks than MS, and recovery is often incomplete, leaving residual disability that accumulates with each relapse. Walking cane use in NMOSD is shaped by the attack-recovery cycle and cumulative residual deficit.
NMOSD vs MS: Why Cane Guidance Differs
Although NMOSD is frequently confused with MS, the walking aid implications differ:
- NMOSD attacks are generally more severe than MS relapses; residual disability after each attack is greater
- NMOSD does not have the progressive phase (secondary progressive MS) in the same way; disability accumulates from attacks, not progressive background degeneration
- Between attacks, NMOSD patients may be stable or near-baseline (unlike progressive MS patients who decline continuously)
- Vision loss (from optic neuritis) is often significant in NMOSD; bilateral visual impairment affects balance
NMOSD Walking Aid by Cumulative Attack Impact
| Attack History | Residual Motor Status | Walking Aid |
|---|---|---|
| First attack, good recovery | Near-normal; possible fatigue and sensory deficits | Cane during recovery phase (weeks 2-12); wean if full recovery achieved |
| First attack, incomplete recovery | Residual weakness; spasticity; sensory loss | Single cane if unilateral weakness; bilateral crutches if bilateral significant weakness |
| Multiple attacks with cumulative deficit | Progressive disability; may be significant | Cane if mild; rollator or wheelchair if moderate-severe |
| Severe attack (cervical cord; bilateral) | Quadriparesis or severe paraparesis | Wheelchair; frame; cane insufficient |
Immunotherapy and Cane Needs
NMOSD management has been transformed by targeted immunotherapies: inebilizumab (CD19 B cell depletion), satralizumab (IL-6 receptor blockade), and eculizumab (complement inhibitor) have demonstrated 77-94% reduction in relapse rates in AQP4-IgG positive NMOSD in clinical trials. With effective attack prevention, disability accumulation is minimised and cane needs may not escalate. Patients who achieve complete relapse suppression may stabilise their cane requirements at current level rather than progressing to heavier aids.
Explore DaiWalk walking canes. Related: Walking Cane for Transverse Myelitis | Walking Cane for Multiple Sclerosis.
